Poulin Y, Ramon M, Rosoph L, et al. - Given that tildrakizumab is a high-affinity, an anti-interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis, researchers used phase 2b/3 trial data to assess the impacts of patient demographic and disease features on tildrakizumab effectiveness. For this investigation, they analyzed data from patients who received placebo, or tildrakizumab 100 or 200 mg, in P05495, reSURFACE 1 and reSURFACE 2. Among individuals randomized in P05495 (N = 355), reSURFACE 1 (N = 772) and 2 (N = 1,090), percentage of PASI 75 and 90 responders were significantly higher for each tildrakizumab dose compared with placebo. Small numerical variations in the effectiveness of tildrakizumab were noted among subgroups defined by patient age and weight, presence of psoriatic arthritis and prior biologic use. These variations were not clinically meaningful, however long-term data analysis may be of value. The effectiveness of tildrakizumab did not differ in relation to patient gender or race, or the number of previously failed conventional systemic therapies. Overall, these outcomes indicate that tildrakizumab may be appropriate in patients with a range of demographic and disease characteristics to treat moderate-to-severe plaque psoriasis.